Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Systemic lupus erythematosus (SLE) patients with discoid lupus erythematosus (DLE) were reported to have milder disease. To test this observation, we used sandwich arrays containing 98 autoantigens to compare autoantibody profiles of SLE subjects without DLE (DLE-SLE+) (N=9), SLE subjects with DLE (DLE+SLE+) (N=10), DLE subjects without SLE (DLE+SLE-) (N=11), and healthy controls (N=11). We validated differentially expressed autoantibodies using immunoassays in DLE-SLE+ (N=18), DLE+SLE+ (N=17), DLE+SLE- (N=23), and healthy subjects (N=22). Arrays showed 15 IgG autoantibodies (10 against nuclear antigens) and 4 IgM autoantibodies that were differentially expressed (q-value<0.05). DLE-SLE+ subjects had higher IgG autoantibodies against double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), double-stranded RNA (dsRNA), histone H2A and H2B, and SS-A (52 kDa) compared with all other groups including DLE+SLE+ subjects (P<0.05). Immunoassays measuring anti-dsDNA, -ssDNA, and -SS-A (52 kDa) IgG autoantibodies showed similar trends (P<0.05). Healthy and DLE+SLE- subjects expressed higher IgM autoantibodies against alpha beta crystallin, lipopolysaccharide, heat-shock cognate 70, and desmoglein-3 compared with DLE+SLE+ and DLE-SLE+ subjects. IgG:IgM ratios of autoantibodies against nuclear antigens progressively rose from healthy to DLE-SLE+ subjects. In conclusion, lower IgG autoantibodies against nuclear antigens in DLE+SLE+ versus DLE-SLE+ subjects suggest that DLE indicates lower disease severity. Higher IgM autoantibodies against selected antigens in healthy and DLE+SLE- subjects may be nonpathogenic.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465644 | PMC |
| http://dx.doi.org/10.1038/jid.2012.207 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus.
Adv Ther
September 2025
Bristol Myers Squibb, Princeton, NJ, 08540, USA.
Background And Objectives: Deucravacitinib, a first-in-class, oral, selective, allosteric tyrosine kinase 2 inhibitor, demonstrated efficacy across the primary endpoint and all key secondary endpoints in the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus (SLE). Here, we describe 2 phase 3 trials [POETYK SLE-1 (NCT05617677), POETYK SLE-2 (NCT05620407)] which will assess the efficacy and safety of deucravacitinib in patients with active SLE. These phase 3 trials have been designed to replicate the successful elements of the phase 2 trial, including its glucocorticoid-tapering strategy and disease activity adjudication.
View Article and Find Full Text PDFKnowledge mapping of plasmacytoid dendritic cells in systemic lupus erythematosus: a bibliometric analysis (2004-2023).
Clin Rheumatol
September 2025
Department of Dermatology, the First Affiliated Hospital, Army Medical University, No. 29 Gaotanyan Street, Shapingba District, Chongqing, China.
Background: Plasmacytoid dendritic cells (pDCs) are a specialized subset of dendritic cells known for their ability to produce type I interferon (IFN I), contributing to antiviral defense and the pathogenesis of autoimmune diseases like systemic lupus erythematosus (SLE). In SLE patients, pDCs are excessively activated, leading to overproduction of IFN-α, which plays a critical role in disease progression. However, no bibliometric analysis has been conducted on the relationship between pDCs and SLE.
View Article and Find Full Text PDFAlterations in erythrocyte deformability, aggregation, and blood viscosity in rheumatoid arthritis and systemic lupus erythematosus patients: A comparative haemorheological analysis.
Clin Hemorheol Microcirc
September 2025
Department of Internal Medicine, Sultan Abdülhamid Han Research & Training Hospital, University of Health Sciences, Istanbul, Turkey.
ObjectivesThis study investigated haemorheological alterations in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).MethodsA total of 136 individuals were enrolled, comprising 52 healthy controls, 51 RA patients, and 33 SLE patients. Blood samples were collected at the University of Health Sciences Sultan Abdulhamid Han Training and Research Hospital in Istanbul, Türkiye.
View Article and Find Full Text PDFDiffuse Alveolar Hemorrhage as a Rare Initial Presentation of Systemic Lupus Erythematosus in Early Pregnancy: A Case Report.
Clin Case Rep
September 2025
Kathmandu Medical College, Kathmandu University Kathmandu Nepal.
Diffuse alveolar hemorrhage is a rare but fatal manifestation of SLE, typically reported in well-established diagnoses of SLE. DAH itself as a presenting symptom is quite rare. In this case, we present a 24-year-old pregnant female at 10 weeks of gestation without a history of SLE presenting with DAH.
View Article and Find Full Text PDFComparative Case Series of Herpes Zoster in Older Immunocompromised Chinese Adults: Clinical, Immunological, and Treatment Profiles in Four Cases Over 60.
Infect Drug Resist
August 2025
Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, People's Republic of China.
Purpose: Herpes zoster poses severe complications in elderly immunocompromised patients, particularly those with altered drug metabolism and renal impairment, impacting quality of life.
Patients And Methods: To evaluate brivudine's efficacy and safety in such cases, we conducted a retrospective case series at Shanghai Skin Disease Hospital, analyzing four Chinese patients (aged 64-84 years) with complex herpes zoster, including systemic lupus erythematosus, diabetes nephropathy, multiple comorbidities, and trigeminal nerve involvement. Selected for their immunocompromised status and prior antiviral failure or renal concerns, patients received oral brivudine (125 mg once daily) with or without intravenous acyclovir, with outcomes assessed via clinical examination, pain scores, and laboratory monitoring over 7-14 days.